相关实验视频

Updated: Jan 17, 2026

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

在耐火性患者中安全使用大麻二醇的实践方法:一篇小型综述

Cristian E Navarro¹

¹School of Medicine, Universidad de Antioquia, Medellín, Colombia.

Frontiers in pharmacology

|September 22, 2025

概括

大麻 (CBD) 是对抗药性的有前途的辅助疗法. 谨慎的剂量,监测药物相互作用,以及管理副作用,如肝酶升高,对于使用纯化CBD口服溶液进行安全有效的治疗至关重要.

科学领域:

药理学药理学是指药理学的学科.
神经学神经学
临床治疗学临床治疗学

背景情况:

耐药性 (DRE) 存在重大治疗挑战.
卡纳比 (CBD) 是一种非精神活性大麻化合物,显示出作为严重综合征的辅助治疗的前景.
高净化99%的CBD口服溶液 (Epidiolex®) 已获得批准并纳入临床实践.

研究的目的:

审查在DRE患者处方和管理高度净化的CBD口服液时的实际考虑.
综合有关剂量,药物相互作用,不良反应和定位策略的证据.
支持临床医生优化DRE的CBD治疗,同时确保患者的安全.

主要方法:

叙事审查综合当前证据.
综合的文献搜索,包括临床试验,评论和现实世界的数据.
专注于实际方面:剂量,药物相互作用,药物不良反应 (ADR) 和剂量定位.

主要成果:

"开始低,慢慢"的方法对于减轻ADRs至关重要.
常见的副作用包括昏昏欲睡,食欲下降和腹.
肝转胺酶的升高,特别是与氨酸并发的,和药物动力学相互作用 (例如,与克洛巴赞) 需要监测和潜在的ASM剂量调整.

结论:

优化DRE的CBD治疗需要了解其使用的实际方面.
逐渐剂量定位和仔细监测是管理副作用和药物相互作用的关键.
本综述为临床医生提供了综合信息,以提高患者的治疗结果和CBDDDRE治疗的安全性.

关键词:

在Cannabidiol中使用.大麻大麻大麻大麻大麻大麻大麻大麻药物耐药性 - 抗药性是一种.发作发作这些

更多相关视频

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings

Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings

Published on: May 7, 2020

相关概念视频

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Epilepsy and Seizures: Overview

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...